MétaCan
Menu
Back to cohort
Record W4388718672 · doi:10.1186/s13063-023-07720-3

Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants

2023· article· en· W4388718672 on OpenAlexaff
Markus Harboe Olsen, Mathias Lühr Hansen, Theis Lange, Christian Gluud, Lehana Thabane, Gorm Greisen, Janus Christian Jakobsen, Adelina Pellicer, Afif El-Kuffash, Agata Bargiel, Ana Alarcón, Andrew Hopper, Anita C. Truttmann, Anja Hergenhan, Anja Klamer, Anna Curley, Anne Marie, Anne Smits, Aslı Memişoğlu, Barbara Królak‐Olejnik, Beata Rzepecka, Begona Loureiro Gonzales, Beril Yaşa, Berndt Urlesberger, Catalina Morales‐Betancourt, Chantal Lecart, Claudia Knöepfli, Cornelia Hagmann, David Healy, Ebru Ergenekon, Eleftheria Hatzidaki, Elena Bergón-Sendín, Eleni Skylogianni, Elżbieta Rafińska‐Ważny, Emmanuele Mastretta, Eugene Dempsey, Eva Valverde, Evangelina Papathoma, Fabio Mosca, Gabriel Dimitriou, Gerhard Pichler, Giovanni Vento, Gitte Holst Hahn, Gunnar Naulaers, Guoqiang Cheng, Hans Fuchs, Hilal Özkan, Itziar Serrano-Viñuales, Iwona Sadowska-Krawczenko, Jáchym Kučera, Jakub Tkaczyk, Jan Miletín, Jan Širc, Jana Baumgärtner, Jonathan Mintzer, Julie De Buyst, Karen McCall, Konstantina Tsoni, Kosmas Sarafidis, Lars Bender, Laura Serrano Lopez, Le Wang, Liesbeth Thewissen, Lina F. Chalak, Ling Yang, Luc Cornette, Luis Arruza, Maria Wilińska, Mariana Baserga, Marie Isabel Rasmussen, Marta Ybarra, Marta Teresa Palacio, Martin Stocker, Massimo Agosti, Merih Çetınkaya, Miguel Alsina Casanova, Monica Fumagalli, Munaf M. Kadri, Mustafa Şenol Akın, Münevver Baş, Nilgün Köksal, Olalla Otero Vaccarello, Olivier Baud, Pamela Zafra, Peter Agergaard, Peter Korček, Pierre Maton, Rebeca Sanchez-Salmador, Ruth del Rio Florentino, Ryszard Lauterbach, Salvador Piris‐Borregas, Saudamini Nesargi, Serife Suna, Shashidhar Appaji Rao, Shujuan Zeng, Silvia Pisoni, Simon Hyttel-Sørensen, Sinem Gülcan Kersin, Siv Fredly, Suna Oğuz, Sylwia Marciniak, Tanja Karen, Tomasz Szczapa, Tone Nordvik, Veronika Karadyova, Xiaoyan Gao, Xin Xu, Zachary A. Vesoulis, Peng Zhang, Zhaoqing Yin

Bibliographic record

VenueTrials · 2023
Typearticle
Languageen
FieldMedicine
TopicNeonatal Respiratory Health Research
Canadian institutionsMcMaster UniversitySt. Joseph’s Healthcare HamiltonImpact
FundersElsass FondenAage og Johanne Louis-Hansens FondCopenhagen Trial Unit, Centre for Clinical Intervention ResearchRigshospitaletSvend Andersen FondenNational Institute of Neurological Disorders and StrokeGentofte Hospital
KeywordsMedicineBronchopulmonary dysplasiaRetinopathy of prematurityGuidelineRandomized controlled trialClinical trialBayes' theoremPrior probabilityPediatricsBayesian probabilityGestational ageStatisticsInternal medicine

Abstract

fetched live from OpenAlex

BACKGROUND: Extremely preterm infants have a high mortality and morbidity. Here, we present a statistical analysis plan for secondary Bayesian analyses of the pragmatic, sufficiently powered multinational, trial-SafeBoosC III-evaluating the benefits and harms of cerebral oximetry monitoring plus a treatment guideline versus usual care for such infants. METHODS: The SafeBoosC-III trial is an investigator-initiated, open-label, randomised, multinational, pragmatic, phase III clinical trial with a parallel-group design. The trial randomised 1601 infants, and the frequentist analyses were published in April 2023. The primary outcome is a dichotomous composite outcome of death or severe brain injury. The exploratory outcomes are major neonatal morbidities associated with neurodevelopmental impairment later in life: (1) bronchopulmonary dysplasia; (2) retinopathy of prematurity; (3) late-onset sepsis; (4) necrotising enterocolitis; and (5) number of major neonatal morbidities (count of bronchopulmonary dysplasia, retinopathy of prematurity, and severe brain injury). The primary Bayesian analyses will use non-informed priors including all plausible effects. The models will use a Hamiltonian Monte Carlo sampler with 1 chain, a sampling of 10,000, and at least 25,000 iterations for the burn-in period. In Bayesian statistics, such analyses are referred to as 'posteriors' and will be presented as point estimates with 95% credibility intervals (CrIs), encompassing the most probable results based on the data, model, and priors selected. The results will be presented as probability of any benefit or any harm, Bayes factor, and the probability of clinical important benefit or harm. Two statisticians will analyse the blinded data independently following this protocol. DISCUSSION: This statistical analysis plan presents a secondary Bayesian analysis of the SafeBoosC-III trial. The analysis and the final manuscript will be carried out and written after we publicise the primary frequentist trial report. Thus, we can interpret the findings from both the frequentists and Bayesian perspective. This approach should provide a better foundation for interpreting of our findings. TRIAL REGISTRATION: ClinicalTrials.org, NCT03770741. Registered on 10 December 2018.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.117
metaresearch head score (Gemma)0.211
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Protocol · Consensus signal: Protocol
Teacher disagreement score0.122
Threshold uncertainty score0.620

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1170.211
Meta-epidemiology (narrow)0.0040.002
Meta-epidemiology (broad)0.0050.011
Bibliometrics0.0030.003
Science and technology studies0.0010.002
Scholarly communication0.0040.002
Open science0.0030.002
Research integrity0.0060.009
Insufficient payload (model declined to judge)0.1220.014

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.359
GPT teacher head0.555
Teacher spread0.196 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreProtocol

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueTrialsSame topicNeonatal Respiratory Health ResearchFrench-language works237,207